Phase II study shows oral tazarotene treatment yields QOL benefits for sufferers of severe acne

Washington D.C. ?? Patients with severe nodulocystic acne treated with oral tazarotene experience a substantial improvement in acne-specific health-related quality of life (HRQOL), according to the results of a Phase II dose-ranging study presented by Patricia S. Walker, M.D., Ph.D., at the annual meeting of the American Academy of Dermatology.

Related Videos
Related Content

Comorbidities Women With Hair Loss May Experience

March 26th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

The Weekly Roundup: March 20-24

March 24th 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Lebrikizumab Demonstrates Promising Results in Atopic Dermatitis

March 24th 2023

Air Pollution from Wildfire Smoke Can Exacerbate Skin Conditions

March 24th 2023

Comorbidities Women With Hair Loss May Experience

March 26th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

The Weekly Roundup: March 20-24

March 24th 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Lebrikizumab Demonstrates Promising Results in Atopic Dermatitis

March 24th 2023

Air Pollution from Wildfire Smoke Can Exacerbate Skin Conditions

March 24th 2023

Comorbidities Women With Hair Loss May Experience

March 26th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

The Weekly Roundup: March 20-24

March 24th 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Lebrikizumab Demonstrates Promising Results in Atopic Dermatitis

March 24th 2023

Air Pollution from Wildfire Smoke Can Exacerbate Skin Conditions

March 24th 2023
© 2023 MJH Life Sciences

All rights reserved.